Cancer

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

– ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are…

10 months ago

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint…

10 months ago

Notice to Convene the Annual General Meeting of Genmab A/S

Company Announcement Genmab A/S to hold Annual General Meeting on Wednesday March 12, 2025 COPENHAGEN, Denmark; February 13, 2025 –…

10 months ago

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse…

10 months ago

Cytovation Appoints Martin Dewhurst to its Board of Directors

Brings over 30 years of life sciences industry experienceCo-led the McKinsey Global Life Sciences practice Bergen, Norway, February 12, 2025…

10 months ago

Gilde Healthcare announces successful sale of health-IT software company Performation to Enovation, part of Legrand

Gilde Healthcare announces successful sale of health-IT software company Performation to Enovation, part of Legrand Exit confirms Gilde's investment strategy…

10 months ago

GRAIL to Announce Fourth Quarter 2024 Financial Results

MENLO PARK, Calif., Feb. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect…

10 months ago

TriNetX and Fujitsu Launch Joint Venture to Increase Japanese Patients’ Access to Life-Changing Medicines

Partnership taps real-world data to accelerate clinical trials, research, and drug development in Japan.   CAMBRIDGE, Mass., Feb. 12, 2025 /PRNewswire/…

10 months ago

Terrain Biosciences emerges from stealth to enable faster therapeutics and vaccine development with better RNA

- Founded by Professors Omar Abudayyeh, Jonathan Gootenberg, and Patrick Hsu leveraging novel AI models and technologies for designing, building,…

10 months ago

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with…

10 months ago